论文部分内容阅读
目的探讨细胞外基质金属蛋白酶诱导因子CD147在膀胱尿路上皮癌组织中的表达及其与临床病理特征和预后的关系。方法应用RT-PCR和Western blot法检测CD147mRNA和蛋白在20例膀胱尿路上皮癌和对应的癌旁组织中的表达情况;应用组织芯片技术和免疫组织化学方法,检测CD147在108例膀胱尿路上皮癌和20例正常膀胱黏膜组织中的表达状况,分析CD147与膀胱尿路上皮癌患者的临床病理学特征及其与预后的关系。结果 CD147mRNA和蛋白在20例膀胱尿路上皮癌组织中的表达水平明显高于相应的癌旁组织,差异有统计学意义(P<0.01)。免疫组织化学检测发现,20例正常膀胱黏膜组织中CD147无表达或呈弱阳性表达,108例膀胱尿路上皮癌组织中CD147阳性表达率为73.1%。CD147表达与膀胱尿路上皮癌患者临床分期、病理分级、肿瘤大小和淋巴结转移密切相关(P<0.05),而与患者的年龄、性别以及肿瘤数目无关(P>0.05)。KaplanMeier生存曲线分析结果表明,高表达CD147的膀胱尿路上皮癌患者的总体生存时间明显短于CD147低表达患者,差异有统计学意义(P<0.01)。单因素分析结果表明,肿瘤临床分期、病理分级、淋巴结转移、肿瘤大小和CD147表达是影响膀胱尿路上皮癌患者预后的重要因素(P<0.05)。COX多因素生存分析结果表明,肿瘤临床分期、病理分级、淋巴结转移和CD147表达是影响膀胱尿路上皮癌患者预后的独立因素(P<0.05)。结论 CD147在膀胱尿路上皮癌中高表达,可能与膀胱尿路上皮癌的进展有关,其表达状态是膀胱尿路上皮癌患者预后的独立因素。
Objective To investigate the expression of extracellular matrix metalloproteinase inducer CD147 in bladder urothelial carcinoma and its relationship with clinicopathological features and prognosis. Methods The expression of CD147 mRNA and protein in 20 cases of bladder urothelial carcinoma and corresponding paracancerous tissues was detected by RT-PCR and Western blot. Tissue microarray and immunohistochemistry were used to detect the expression of CD147 on 108 cases of bladder urinary tract Skin cancer and 20 cases of normal bladder mucosa. The clinicopathological features of CD147 and bladder urothelial carcinoma were analyzed. The relationship between CD147 and prognosis was analyzed. Results The expression of CD147 mRNA and protein in 20 cases of bladder urothelial carcinoma was significantly higher than that in the corresponding paracancerous tissues (P <0.01). Immunohistochemical staining revealed that CD147 was not expressed or weakly positive in 20 cases of normal bladder mucosa. The positive rate of CD147 in 108 cases of bladder urothelial carcinoma was 73.1%. The expression of CD147 was closely related to the clinical stage, pathological grade, tumor size and lymph node metastasis in bladder urothelial carcinoma (P <0.05), but not with the age, sex and tumor number (P> 0.05). KaplanMeier survival curve analysis showed that the overall survival time of CD147-positive patients with bladder urothelial carcinoma was significantly shorter than that of patients with low CD147 expression (P <0.01). The results of univariate analysis showed that the clinical stage, pathological grade, lymph node metastasis, tumor size and CD147 expression were the important factors influencing the prognosis of patients with bladder urothelial carcinoma (P <0.05). COX multivariate survival analysis showed that clinical stage, pathological grade, lymph node metastasis and CD147 expression were independent prognostic factors of bladder urothelial carcinoma (P <0.05). Conclusion The high expression of CD147 in bladder urothelial carcinoma may be related to the progress of bladder urothelial carcinoma. The expression of CD147 is an independent prognostic factor in bladder urothelial carcinoma.